KR102731128B1 - Kv7 채널 활성화제 조성물 및 이의 사용 방법 - Google Patents

Kv7 채널 활성화제 조성물 및 이의 사용 방법 Download PDF

Info

Publication number
KR102731128B1
KR102731128B1 KR1020207029659A KR20207029659A KR102731128B1 KR 102731128 B1 KR102731128 B1 KR 102731128B1 KR 1020207029659 A KR1020207029659 A KR 1020207029659A KR 20207029659 A KR20207029659 A KR 20207029659A KR 102731128 B1 KR102731128 B1 KR 102731128B1
Authority
KR
South Korea
Prior art keywords
imidazol
benzo
pharmaceutically acceptable
delete delete
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207029659A
Other languages
English (en)
Korean (ko)
Other versions
KR20200133259A (ko
Inventor
마이클 이. 보직
스캇 에스. 해러드
린 레스닉
조지 티. 토팔로브
저스틴 케이. 벨라르디
찰스 에이. 플렌테지
데이비드 에이. 마레스카
제임스 에스. 헤일
Original Assignee
놉 바이오사이언시스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 놉 바이오사이언시스 엘엘씨 filed Critical 놉 바이오사이언시스 엘엘씨
Priority to KR1020247037753A priority Critical patent/KR102868652B1/ko
Publication of KR20200133259A publication Critical patent/KR20200133259A/ko
Application granted granted Critical
Publication of KR102731128B1 publication Critical patent/KR102731128B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020207029659A 2018-03-19 2019-03-19 Kv7 채널 활성화제 조성물 및 이의 사용 방법 Active KR102731128B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247037753A KR102868652B1 (ko) 2018-03-19 2019-03-19 Kv7 채널 활성화제 조성물 및 이의 사용 방법

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862644932P 2018-03-19 2018-03-19
US201862644902P 2018-03-19 2018-03-19
US62/644,932 2018-03-19
US62/644,902 2018-03-19
US201862663438P 2018-04-27 2018-04-27
US62/663,438 2018-04-27
US201862697198P 2018-07-12 2018-07-12
US62/697,198 2018-07-12
PCT/US2019/023039 WO2019183148A1 (en) 2018-03-19 2019-03-19 Kv7 channel activators compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247037753A Division KR102868652B1 (ko) 2018-03-19 2019-03-19 Kv7 채널 활성화제 조성물 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20200133259A KR20200133259A (ko) 2020-11-26
KR102731128B1 true KR102731128B1 (ko) 2024-11-18

Family

ID=67905138

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207029659A Active KR102731128B1 (ko) 2018-03-19 2019-03-19 Kv7 채널 활성화제 조성물 및 이의 사용 방법
KR1020247037753A Active KR102868652B1 (ko) 2018-03-19 2019-03-19 Kv7 채널 활성화제 조성물 및 이의 사용 방법
KR1020257032902A Pending KR20250150168A (ko) 2018-03-19 2019-03-19 Kv7 채널 활성화제 조성물 및 이의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247037753A Active KR102868652B1 (ko) 2018-03-19 2019-03-19 Kv7 채널 활성화제 조성물 및 이의 사용 방법
KR1020257032902A Pending KR20250150168A (ko) 2018-03-19 2019-03-19 Kv7 채널 활성화제 조성물 및 이의 사용 방법

Country Status (13)

Country Link
US (5) US10851067B2 (https=)
EP (1) EP3768677A4 (https=)
JP (2) JP7757036B2 (https=)
KR (3) KR102731128B1 (https=)
CN (6) CN118955402A (https=)
AU (3) AU2019239955B2 (https=)
BR (1) BR112020018933A2 (https=)
CA (1) CA3093976A1 (https=)
IL (2) IL277419B2 (https=)
MX (2) MX2020009693A (https=)
SG (1) SG11202008030WA (https=)
WO (1) WO2019183148A1 (https=)
ZA (1) ZA202308070B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3572405T1 (sl) * 2014-09-12 2023-12-29 Biohaven Therapeutics Ltd. Amidi benzoimidazol-1,2-il kot aktivatorji kanalov kv 7
CN118955402A (zh) * 2018-03-19 2024-11-15 诺普生物科学有限责任公司 Kv7通道激活剂组合物和使用方法
BR112022004847A2 (pt) * 2019-09-17 2022-06-07 Knopp Biosciences Llc Método para tratar uma doença ou distúrbio de neurodesenvolvimento
CA3266454A1 (en) * 2022-08-30 2024-03-07 Biohaven Therapeutics Ltd. POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS
AU2023338196A1 (en) * 2022-09-06 2025-04-10 Biohaven Therapeutics Ltd. Combination therapies including metal channel activators
KR20260049605A (ko) * 2023-08-10 2026-04-14 바이오하벤 테라퓨틱스 리미티드 Kv7.2/7.3 칼륨 채널 활성제의 서방형 제형
IL326832A (en) * 2023-09-15 2026-04-01 Biohaven Therapeutics Ltd Methods for treating epilepsy and related disorders using potent and selective potassium channel activators
WO2025103406A1 (zh) * 2023-11-15 2025-05-22 南京明德新药研发有限公司 6并5杂芳基衍生物及其应用
WO2025137661A1 (en) * 2023-12-22 2025-06-26 Biohaven Therapeutics Ltd. Combination treatment of neurological disorders
US20260049061A1 (en) * 2024-03-18 2026-02-19 HUMANWELL PHARMACEUTICAL US, Inc. Small molecules as kcnq2/3 (kv7.2/3) channel activators and their medical use thereof
WO2026042005A1 (en) 2024-08-18 2026-02-26 Biohaven Therapeutics Ltd. Prodrugs of benzimidazol-1,2-yl amide compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080214613A1 (en) 2005-05-18 2008-09-04 Paul Renton Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity
WO2015023958A1 (en) 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
US20160031875A1 (en) 2013-03-15 2016-02-04 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
US20160075663A1 (en) * 2014-09-12 2016-03-17 Knopp Biosciences Llc BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0772181B2 (ja) 1989-06-26 1995-08-02 株式会社大塚製薬工場 ベンズイミダゾール誘導体
JPH0772181A (ja) 1993-09-03 1995-03-17 Advantest Corp 電位波形測定方法および装置
GB9413724D0 (en) 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
EP2186804B1 (en) 2007-08-10 2015-06-17 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and pest control agent
TWI482768B (zh) 2007-11-22 2015-05-01 Zenyaku Kogyo Kk 雜環化合物之非晶質體、含有其之固體分散體、藥劑及其製法
GB0723794D0 (en) 2007-12-05 2008-01-16 Lectus Therapeutics Ltd Potassium ion channel modulators and uses thereof
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
WO2010051819A1 (en) 2008-11-10 2010-05-14 Neurosearch A/S Novel 2,3-diamino-quinazolinone derivatives and their medical use
US8232273B2 (en) 2008-12-19 2012-07-31 Genentech, Inc. Heterocyclic compounds and methods of use
CA2804165C (en) 2010-07-08 2015-02-24 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
CN103168032A (zh) 2010-08-05 2013-06-19 安美基公司 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物
CN118955402A (zh) * 2018-03-19 2024-11-15 诺普生物科学有限责任公司 Kv7通道激活剂组合物和使用方法
BR112022004847A2 (pt) * 2019-09-17 2022-06-07 Knopp Biosciences Llc Método para tratar uma doença ou distúrbio de neurodesenvolvimento

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080214613A1 (en) 2005-05-18 2008-09-04 Paul Renton Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity
US20160031875A1 (en) 2013-03-15 2016-02-04 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
WO2015023958A1 (en) 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
US20160075663A1 (en) * 2014-09-12 2016-03-17 Knopp Biosciences Llc BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
US20170114022A1 (en) * 2014-09-12 2017-04-27 Knopp Biosciences Llc BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS

Also Published As

Publication number Publication date
IL277419B2 (en) 2024-07-01
US12286408B2 (en) 2025-04-29
AU2019239955A1 (en) 2020-10-01
EP3768677A4 (en) 2021-12-22
AU2024202496A1 (en) 2024-05-09
US11724990B2 (en) 2023-08-15
IL277419A (en) 2020-11-30
CN118955402A (zh) 2024-11-15
KR20200133259A (ko) 2020-11-26
WO2019183148A1 (en) 2019-09-26
SG11202008030WA (en) 2020-10-29
MX2020009693A (es) 2021-01-08
CN119118926A (zh) 2024-12-13
US11261162B2 (en) 2022-03-01
IL310136A (en) 2024-03-01
ZA202308070B (en) 2025-04-30
CA3093976A1 (en) 2019-09-26
KR20250150168A (ko) 2025-10-17
BR112020018933A2 (pt) 2020-12-29
CN112771039A (zh) 2021-05-07
MX2023001153A (es) 2023-02-22
US20240002349A1 (en) 2024-01-04
CN118955401A (zh) 2024-11-15
US10851067B2 (en) 2020-12-01
EP3768677A1 (en) 2021-01-27
CN118955403A (zh) 2024-11-15
AU2023266373A1 (en) 2023-12-07
NZ767228A (en) 2023-11-24
CN118955400A (zh) 2024-11-15
JP2024026104A (ja) 2024-02-28
JP2021518844A (ja) 2021-08-05
AU2019239955B2 (en) 2023-08-24
US20190284142A1 (en) 2019-09-19
KR20240163771A (ko) 2024-11-19
IL277419B1 (en) 2024-03-01
US20210130299A1 (en) 2021-05-06
KR102868652B1 (ko) 2025-10-13
US20230000831A1 (en) 2023-01-05
US20260062389A1 (en) 2026-03-05
AU2023266373B2 (en) 2024-02-08
JP7757036B2 (ja) 2025-10-21

Similar Documents

Publication Publication Date Title
KR102731128B1 (ko) Kv7 채널 활성화제 조성물 및 이의 사용 방법
KR101851810B1 (ko) 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 신규 화합물
KR20030076717A (ko) 인지 장애의 치료를 위한 니코틴 수용체 부분 아고니스트,에스트로겐, 선택적 에스트로겐 조정자 또는 비타민 ｅ와함께, ｇａｂａａ 역아고니스트의 용도
HK40118422A (zh) Kv7通道激活剂组合物和使用方法
HK40119318A (zh) Kv7通道激活剂组合物和使用方法
HK40119631A (zh) Kv7通道激活剂组合物和使用方法
HK40120047A (zh) Kv7通道激活剂组合物和使用方法
HK40119317A (zh) Kv7通道激活剂组合物和使用方法
CN118678954A (zh) 作为kv7通道激活剂的吡唑基化合物
AU2024225907A1 (en) Hydroxyalkyl and methoxyalkyl tryptamines
WO2023164538A1 (en) Pyrazolyl compounds as kv7 channel activators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201015

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220315

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240412

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20240719

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240920

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241112

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241112

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241113

End annual number: 3

Start annual number: 1

PG1601 Publication of registration